Efficacy and Safety of IVIG-L in ITP Patients

Inclusion Criteria: * Patients with chronic ITP with a platelet count of about 20x109/L and at high risk of bleeding * Patients with chronic ITP with a platelet count of about 20x109/L, who have to undergo surgery * A stable clinical situation (no activity of any other disease) * Age at least 18 yrs * The patient/legally acceptable representative has signed the consent form Exclusion Criteria: * The presence of another autoimmune disease related with thrombocytopenia such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) or nephritis * Patients with drug-induced thrombocytopenia or immunologic thrombocytopenia of infectious origin (in particular, Hepatitis, Epstein-Barr virus, Toxoplasma, HIV) * Massive splenomegaly * Treatment with any other investigational drug within 7 days before study entry or previous enrolment in this study * Having an ongoing progressive terminal disease, including HIV infection * Known with allergic reactions against human plasma, plasma products or intravenous immunoglobulin * Presence of conditions predisposing for bleeding: anaemia (hemoglobin \< 5.5 mmol/L), renal or urogenital disease, malignant disease (with the exception of basalioma, cervix carcinoma in situ), history of intracranial or aortic aneurysm, stroke, oeso-gastro-intestinal disorders with a bleeding potential, severe hypertension (diastole \> 110 mm Hg). * Use of corticosteroids for an acute situation within 7 days before study entry. Patients using corticosteroids prophylactically can be included * Splenectomy in the previous two weeks * Renal insufficiency (plasma creatinine \> 115µmol/L) * Pregnancy or lactation * Known with insufficiency of coronary or cerebral circulation * IgA deficiency and anti-IgA antibodies